contribution of the purged peripheral blood or marrow 
cells to hematopoietic recovery by the normal stem cells. 
Differences will be analyzed by the students T test to 
determine if a statistically significant difference 
exists between the frequency by the two viruses after 
transplants. 
10.3 Stopping Rules: If three successive patients have 
treatment deaths due to failure to engraft, delayed 
hematopoietic recovery, or any treatment related cause, 
the trial will be stopped. 
10.4 Reporting requirements: All adverse outcomes will be 
reported to the RAC, the FDA, and the NCI. 
Recombinant DNA Research, Volume 15 
[871] 
